AR045697A1 - Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo - Google Patents

Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo

Info

Publication number
AR045697A1
AR045697A1 ARP040102465A ARP040102465A AR045697A1 AR 045697 A1 AR045697 A1 AR 045697A1 AR P040102465 A ARP040102465 A AR P040102465A AR P040102465 A ARP040102465 A AR P040102465A AR 045697 A1 AR045697 A1 AR 045697A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
group
cycloalkyl
haloalkyl
Prior art date
Application number
ARP040102465A
Other languages
English (en)
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of AR045697A1 publication Critical patent/AR045697A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Los compuestos de la presente son útiles para la prevención o el tratamiento de trastornos metabólicos y sus complicaciones, tales como diabetes y obesidad. Reivindicación 1: Un compuesto de fórmula (1), o una sal, hidrato o solvato del mismo aceptable desde el punto de vista farmacéutico; donde, A y B son cada uno independientemente alquileno C1-3 opcionalmente substituido con 1 a 4 substituyentes seleccionados del grupo formado por alquilo C1-3, alcoxi C1-4, carboxi, ciano, haloalquilo C1-3 y halógeno; D es O, S, S (O),S(O)2, CR1R2 o N-R2, donde R, se selecciona del grupo formado por H, alquilo C1-8, alcoxi C1-4, halógeno y hidroxilo; E es N, C o CR3, donde R3 es H o alquilo C1-8; la línea punteada es un enlace simple cuando E es N o CR3, o un doble enlace cuando E es C; K es un cicloalquileno C3-6 o alquileno C1-3 donde cada uno está opcionalmente substituido con 1 a 4 substituyentes seleccionados del grupo formado por alquilo C1-3, alcoxi C1-4, carboxi, ciano, haloalquilo C1-3 y halógeno; o K es un enlace; Q es NR4, O, S, S(O) o S(O)2, donde R4 es H o alquilo C1-8 y el alquilo C1-8 está opcionalmente substituido con dialquilamina C2-8; T es N o CR5; M es N o CR6; J es N o CR7; U es C o N; V es N, CR8 o V es un enlace; W es N o C; X es O, S, N, CR9 o NR11;Y es O, S, N, CR10 o NR12; Z es C o N; R5, R6, R7, R8, R9 y R10 se seleccionan cada uno independientemente del grupo formado por H, aciloxi C1-5, alquenilo C2-6, alcoxi C1-4, alquilo C1-8, alquilcarboxamida C1-4, alquinilo C2-6, alquilsulfonamida C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alquiltio C1-4, alquilureilo C1-4, amino, alquilamino C1-4, dialquilamino C2-8, carboxamida, ciano, cicloalquilo C3-6, dialquilcarboxamida C2- 6, dialquilsulfonamida C2-6, halógeno, haloalquioxi C1-4, haloalquilo C1-4, haloalquilsulfinilo C1-4, haloalquilsulfonilo C1-4, haloalquiltio C1-4, hidroxilo, hidroxilamino y nitro; donde dicho alquenilo C2-6, alquilo C1-8, alquinilo C2-6 y cicloalquilo C3-6 están opcionalmente substituido con 1, 2, 3 o 4 substituyentes seleccionados del grupo formado por acilo C1-5, aciloxi C1-5, alcoxi C1-4, alquilamino C1-4, alquilcarboxamida C1-4, alquiltiocarboxamida C1-4, alquilsulfonamida C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alquiltio C1-4, alquiltioureilo C1-4, alquilureilo C1-4, amino, carbo-alcoxi C1-6, carboxamida, carboxi, ciano, dialquilamino C2-8, dialquilcarboxamida C2-6, dialquiltiocarboxamida C1-4, dialquilsulfonamida C2-6, alquiltioureilo C1-4, haloalcoxi C1-4, haloalquilo C1-4, haloalquilsulfinilo, haloalquilsulfonilo C1-4, haloalquilo C1-4, haloalquiltio C1-4, halógeno, hidroxilo, hidroxilamino y nitro; R11 y R12 se seleccionan cada uno independientemente del grupo formado por alquenilo C2-6, alquilo C1-8, alquinilo C2-6 o cicloalquilo C3-6 cada uno opcionalmente substituido con 1, 2, 3 o 4 substituyentes seleccionados entre acilo C1-5, aciloxi C1-5, alcoxi C1-4, alquilamino C1-4, alquilcarboxamida C1-4, alquiltiocarboxamida C1-4, alquilsulfonamida C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alquiltio C1-4, alquiltioureilo C1-4, alquilureilo C1-4, amino, carbo-alcoxi C1-6, carboxamida, carboxi, ciano, dialquilamino C2- 8, dialquilcarboxamida C2-6, dialquiltiocarboxamida C1-4, dialquilsulfonamida C2-6, alquiltioureilo C1-4, haloalcoxi C1-4, haloalquilo C1-4, haloalquilsulfinilo C1-4, haloalquilsulfonilo C1-4, haloalquilo C1-4, haloalquiltio C1-4, halógeno, hidroxilo, hidroxilamino y nitro; Ar1 es arilo o heteroarilo cada uno opcionalmente substituido con R13, R14, R15, R16, y R17; donde R13 se selecciona del grupo formado por acilo C1-5, acilsulfonamida C1-6, aciloxi C1-5, alquenilo C2-6, alcoxi C1-4, alquilo C1-8, alquilamino C1-4, alquilcarboxamida C1-6, alquiltiocarboxamida C1-4, alquinilo C2-6, alquilsulfonamida C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alquiltio C1-4, alquiltioureilo C1-4, alquilureilo C1-4, amino, arilsulfonilo, carbamimidoilo, carbo-alcoxi C1-6, carboxamida, carboxi, ciano, cicloalquilo C3-7, cicloalquiloxi C3-7, dialquilamino C2-6, dialquilcarboxamida C2-6, dialquiltiocarboxamida C2-6, guanidinilo, halógeno, haloalcoxi C1-4, haloalquilo C1-4, haloalquilsulfinilo C1-4, haloalquilsulfonilo C1-4, haloalquiltio C1-4, heterocíclico, oxiheterocíclico, sulfoniloheterocíclico, carbonilo heterocíclico, heteroarilo, heteroarilcarbonilo, hidroxilo, nitro, oxo-cicloalquilo C4-7, fenoxi, fenilo, sulfonamida, ácido sulfónico, y tiol, y donde acilo C1-5, acilsulfonamida C1-6, alcoxi C1-4, alquilo C1-8, alquilamino C1-4, alquilsulfonamida C1-4, alquilsulfonilo C1-4, alquiltio C1-4, arilsulfonilo, carbamimidoilo, dialquilamino C2-6, heterocíclico, carbonilo heterocíclico, heteroarilo, fenoxi y fenilo están opcionalmente substituido con 1 a 5 substituyentes seleccionados independientemente del grupo formado por acilo C1-5, aciloxi C1-5, alquenilo C2-6, alcoxi C1-4, alquilo C1-7, alquilamino C1-4, alquilcarboxamida C1-4, alquinilo C2-6, alquilsulfonamida C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alquiltio C1-4, alquilureílo C1-4, carbo-alcoxi C1-4, carboxamida, carboxi, ciano, cicloalquilo C3-7, cicloalquiloxi C3-7, dialquilamino C2-6, dialquilcaboxamida C2-6, halógeno, haloalcoxi C1-4, haloalquilo C1-4, halalquilsulfinilo C1-4, haloalquilsulfonilo C1-4, haloalquiltio C1-4, heteroarilo, heterocíclico, hidroxilo, nitro, fenilo y fosfonoxi, donde dichos alquilo C1-7 y alquilcarboxamida C1-4 están cada uno opcionalmente substituido con 1 a 5 substituyentes seleccionados del grupo formado por alcoxi C1-4 e hidroxi; o R13 es un grupo de fórmula (2), donde "p" y "r" son independientemente 0, 1, 2 ó 3; y R18 es H, acilo C1-5, alquenilo C2-6, alquilo C1-8, alquilcarboxamida C1-4, alquinilo C2-6, alquilsulfonamida C1-4, carbo-alcoxi C1-6, carboxamida, carboxi, ciano, cicloalquilo C3-7, dialquilcarboxamida C2-6, halógeno, heteroarilo o fenilo, y donde dichos heteroarilo o fenilo están opcionalmente substituidos con 1 a 5 substituyentes seleccionados independientemente del grupo formado por alcoxi C1-4, amino, alquilamino C1-4, alquinilo C2-6, dialquilamino C2-8, halógeno, haloalcoxi C1-4, haloalquilo C1- 4 e hidroxilo; R14, R15, R16, y R17 se seleccionan cada uno independientemente del grupo formado por H, acilo C1-5, aciloxi C1-5, alquenilo C2-6, alcoxi C1-4, alquilo C1-8, alquilcarboxamida C1-4, C2-6alquinilo C2-6, alquilsulfonamida C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alquiltio C1-4, alquilureilo C1-4, carbo-alcoxi C1-6, carboxamida, carboxi, ciano, cicloalquilo C3-7, dialquilcarboxamida C2-6, halógeno, haloalcoxi C1-4, haloalquilo C1-4, haloalquilsulfinilo C1-4, haloalquilsulfonilo C1-4, haloalquiltio C1-4, hidroxilo y nitro; o dos grupos adyacentes seleccionados del grupo formado por R14, R15, R16 y R17 forman un grupo cicloalquilo, cicloalquenilo o heterocíclico de 5, 6 o 7 miembros con Ar1 donde el grupo de 5, 6 o 7 miembros está opcionalmente substituido con halógeno; y R2 se selecciona del grupo formado por alquilo C1-8, alquinilo C2-6, amino, arilo, carboxamida, carboxi, ciano, cicloalquilo C3-6, haloalcoxi C1-4, haloalquilo C1-4, halógeno, heteroarilo e hidroxilo; y donde alquilo C1-8, arilo y heteroarilo están opcionalmente substituidos con 1 a 5 substituyentes seleccionados del grupo formado por acilo C1-5, aciloxi C1-5, alcoxi C1-4, alquilo C1-8, alquilamino C1-4, alquilcarboxamida C1-4, alquiltiocarboxamida C1-4, alquilsulfonamida C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alquiltio C1-4, alquiltioureilo C1-4, alquilureilo C1-4, amino, carbo-alcoxi C1-6, carboxamida, carboxi, ciano, cicloalquilo C3-6, cicloalquil C3-6- heteroalquileno C1-3, dialquilamino C2-8, dialquilcarboxamida C2-6, dialquiltiocarboxamida C2-6, dialquilsulfonamida C2-6, alquiltioureilo C1-4, haloalcoxi C1-4, haloalquilo C1-4, haloalquilsulfinilo C1-4, haloalquilsulfonilo C1-4, haloalquilo C1-4, haloalquiltio C1-4, halógeno, heterocíclico, hidroxilo, hidroxilamino y nitro; o R2 es -Ar2-Ar3 donde Ar2 y Ar3 son cada uno independientemente arilo o heteroarilo opcionalmente substituido con 1 a 5 substituyentes seleccionados del grupo formado por H, acilo C1-5, aciloxi C1-5, alcoxi C1-4, alquilo C1-8, alquilcarboxamida C1-4, alquiltiocarboxamida C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alquiltio C1-4, amino, alquilamino C1-4, carbo-alcoxi C1-6, carboxamida, carboxi, ciano, cicloalquilo C3-6, dialquilamino C2-8, dialquilcarboxamida C2-6, haloalcoxi C1-4, haloalquilo C1-4, halógeno, hidroxilo y nitro; o R2 es un grupo de fórmula (3), donde R19 es H, alquilo C1-8, cicloalquilo C3-7, arilo, heteroarilo u OR21; y R20 es F, Cl, Br, CN o NR22R23; donde R21 es H, alquilo C1-8 o cicloalquilo C3-7, y R22 y R23 son independientemente H, alquilo C1-8, cicloalquilo C3-7, arilo o heteroarilo; o R2 es un grupo de fórmula (4), donde G es: i) -C(O)-, -C(O)NR25-, -NR25C(O)-, -NR25- , -NR25C(O)O-, -OC(O)NR25-, -CR25R26NR27C(O)-, -CR25R26C(O)NR27-, -C(O)O-, -OC(O)-, -C(S)-, -C(S)NR25-, -C(S)O-, -OC(S)-, -CR25R26-, -O-, -S-, -S(O)-, -S(O)2- o un enlace donde D es CR2R3; o ii) -CR25R26C(O)-, -C(O)-, -CR25R26C(O)NR27-, -C(O)NR25-, - C(O)O-, -C(S)-, -C(S)NR25-, -C(S)O-, -CR25R26-, -S(O)2-, o un enlace donde D es NR2; donde R25, R26 y R27 son cada uno independientemente H o alquilo C1-8; y R24 es H, alquilo C1-8, cicloalquilo C3-7, fenilo, heteroarilo, o heterocíclico cada uno opcionalmente substituido con 1 a 5 substituyentes seleccionados del grupo formado por acilo C1-5, aciloxi C1-5, alquenilo C2-6, alcoxi C1-4, alquilo C1-7, alquilamino C1-4, alquilcarboxamida C1-4, alquiltiocarboxamida C1-4, alquilsulfonamida C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alquiltio C1-4, alquiltioureilo C1-4, alquilureilo C1-4, amino, carbo-alcoxi C1-6, carboxamida, carboxi, ciano, cicloalquilo C3-7, dialquilamino C2-8, dialquilcarboxamida C2-6, dialquiltiocarboxamida C2-6, dialquilsulfonamida C2-6, alquiltioureilo C1-4, haloalcoxi C1-4, haloalquilo C1-4, haloalquilsulfinilo C1-4, haloalquilsulfonilo C1-4, haloalquil
ARP040102465A 2003-07-14 2004-07-13 Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo AR045697A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48744303P 2003-07-14 2003-07-14
US51064403P 2003-10-10 2003-10-10

Publications (1)

Publication Number Publication Date
AR045697A1 true AR045697A1 (es) 2005-11-09

Family

ID=34083412

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP040102465A AR045697A1 (es) 2003-07-14 2004-07-13 Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
ARP060101765A AR053863A2 (es) 2003-07-14 2006-05-02 Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos ralacionados con el mismo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP060101765A AR053863A2 (es) 2003-07-14 2006-05-02 Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos ralacionados con el mismo

Country Status (23)

Country Link
US (5) US7132426B2 (es)
EP (4) EP2287165A3 (es)
JP (2) JP4920410B2 (es)
KR (1) KR20060056944A (es)
CN (1) CN102417508A (es)
AR (2) AR045697A1 (es)
AU (1) AU2004257267B2 (es)
BR (1) BRPI0412689A (es)
CA (1) CA2532971A1 (es)
CR (1) CR8118A (es)
EA (1) EA010023B1 (es)
EC (1) ECSP066284A (es)
IL (1) IL172621A0 (es)
IS (1) IS8295A (es)
MA (1) MA28130A1 (es)
MX (1) MXPA06000554A (es)
MY (1) MY157911A (es)
NO (1) NO20060688L (es)
NZ (1) NZ544200A (es)
RS (1) RS20060018A (es)
TN (1) TNSN06005A1 (es)
TW (1) TWI335328B (es)
WO (1) WO2005007658A2 (es)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1434763B1 (en) * 2001-10-12 2018-01-17 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1a antagonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CA2532971A1 (en) * 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7824723B2 (en) 2003-09-12 2010-11-02 Snyder Llc Grape flavored pome fruit
AU2005271669A1 (en) * 2004-08-03 2006-02-16 Merck & Co., Inc. 1,3-disubstituted heteroaryl NMDA/NR2B antagonists
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060128729A1 (en) * 2004-11-23 2006-06-15 Manojit Pal Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
EP1746099A1 (en) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
US9597314B2 (en) * 2005-03-22 2017-03-21 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
AU2013206201B2 (en) * 2005-03-22 2016-06-16 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
KR101523776B1 (ko) 2005-07-19 2015-05-28 아제반 파마슈티칼스, 인코퍼레이티드 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질
WO2007013964A1 (en) 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
MX2008003634A (es) * 2005-09-16 2009-10-08 Arena Pharm Inc Moduladores del metabolismo y tratamiento de los trastornos metabolicos.
JP2009528365A (ja) * 2006-02-28 2009-08-06 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン及びキナゾリン誘導体
DK1971862T3 (da) * 2006-04-11 2011-02-14 Arena Pharm Inc Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
TW200811147A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
EP2043744A2 (en) * 2006-07-13 2009-04-08 SmithKline Beecham Corporation Chemical compounds
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US8318751B2 (en) * 2007-04-20 2012-11-27 Merck Sharp & Dohme Corp. Pyrimidinone derivatives and methods of use thereof
JP2010526145A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，６］および［６，７］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
JP2010526146A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AU2008258487B2 (en) * 2007-06-08 2012-11-15 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
CA2687912C (en) 2007-06-08 2015-11-03 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
WO2008148851A1 (en) * 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
EP2170864B1 (en) 2007-07-17 2011-09-14 Bristol-Myers Squibb Company Pyridone gpr119 g protein-coupled receptor agonists
BRPI0814294A2 (pt) * 2007-07-19 2015-02-03 Metabolex Inc Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas.
AU2008302570B2 (en) 2007-09-20 2012-05-31 Irm Llc Compounds and compositions as modulators of GPR119 activity
CA2719507C (en) * 2008-03-31 2018-03-27 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2009143049A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
PE20100083A1 (es) 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
EP2318404B1 (en) * 2008-07-16 2013-08-21 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
JP2011528369A (ja) * 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびそれらの使用方法
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20100130476A1 (en) * 2008-11-12 2010-05-27 The Scripps Research Institute Compounds that induce pancreatic beta-cell expansion
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
CN102245604A (zh) * 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
CA2747807A1 (en) 2008-12-23 2010-07-01 Bernard R. Neustadt Pyrimidine derivatives and methods of use thereof
CA2747809A1 (en) 2008-12-23 2010-07-01 Joel M. Harris Bicyclic heterocycle derivatives and methods of use thereof
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US20120016119A1 (en) * 2009-01-22 2012-01-19 Yasunori Tsuboi NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND
WO2010095663A1 (ja) 2009-02-18 2010-08-26 武田薬品工業株式会社 縮合複素環化合物
US8580807B2 (en) 2009-04-03 2013-11-12 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
US20100285145A1 (en) * 2009-05-08 2010-11-11 Pfizer Inc Gpr 119 modulators
CA2764021C (en) * 2009-06-05 2014-04-22 Pfizer Inc. Gpr 119 modulators
WO2011041154A1 (en) * 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CN102596961B (zh) 2009-10-30 2015-12-02 詹森药业有限公司 咪唑并[1，2-b]哒嗪衍生物及其作为PDE10抑制剂的用途
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US20130065883A1 (en) 2010-02-18 2013-03-14 Centro Nacional de Investigaceiones Oncologicas (CNIO) Triazolo [4, 5- B] Pyridin Derivatives
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
BR112012025590A2 (pt) 2010-04-08 2016-06-21 Bristol Myers Squibb Co análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
CN102971311B (zh) 2010-05-06 2015-07-08 百时美施贵宝公司 作为gpr119调节剂的二环杂芳基化合物
EP2566862B1 (en) 2010-05-06 2015-09-16 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
US8673894B2 (en) 2010-05-07 2014-03-18 Hoffmann-La Roche Inc. 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
JP5847813B2 (ja) 2010-06-23 2016-01-27 シマベイ セラピューティクス， インコーポレーテッド ５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
CA2804001C (en) 2010-07-01 2021-02-09 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EA031618B1 (ru) 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Соединения-модуляторы gpr-119
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP2850073B1 (en) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2872216C (en) 2012-06-26 2021-07-20 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
PT2909192T (pt) 2012-10-16 2017-08-04 Janssen Pharmaceutica Nv Moduladores de ror-gama-t quinolinilo ligados por metileno
MX2015004784A (es) 2012-10-16 2015-08-14 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a fenilo de receptor nuclear de acido retinoico-gamma-t.
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
BR112015010412A2 (pt) 2012-11-08 2017-07-11 Pfizer compostos heteroaromáticos e seu uso como ligantes de dopamina d1
EP2970211B1 (en) * 2013-03-15 2017-07-26 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
CN105848483A (zh) 2013-10-15 2016-08-10 詹森药业有限公司 RORγt 的喹啉基调节剂
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
WO2015057629A1 (en) * 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv ALKYL LINKED QUINOLINYL MODULATORS OF RORyt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105226B1 (en) 2014-02-13 2019-09-04 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CR20200199A (es) 2014-02-13 2020-06-19 Incyte Corp CICLOPROPILAMINA COMO INHIBIDOR DE LA LSD1 (Divisional 2016-0396)
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
KR101651505B1 (ko) 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
TWI765860B (zh) 2015-08-12 2022-06-01 美商英塞特公司 Lsd1抑制劑之鹽
EP3352750A4 (en) 2015-11-04 2018-08-01 Hyundai Pharm Co., Ltd. Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
JP6999574B2 (ja) 2016-04-22 2022-01-18 インサイト・コーポレイション Ｌｓｄ１阻害剤の製剤
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
KR20190035752A (ko) 2016-08-03 2019-04-03 사이머베이 쎄라퓨틱스, 인코퍼레이티드 염증성 위장 질환 또는 위장 상태를 치료하기 위한 옥시메틸렌 아릴 화합물
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
JP2020524181A (ja) 2017-06-19 2020-08-13 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｎａｆｌｄおよびｎａｓｈの治療のための化合物および方法
CN111295373A (zh) 2017-09-15 2020-06-16 阿泽凡药物公司 用于治疗脑损伤的组合物和方法
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
KR20230057341A (ko) 2020-07-02 2023-04-28 인사이트 코포레이션 Jak2 v617f 억제제로서 삼환계 우레아 화합물
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139705A (en) * 1977-05-20 1979-02-13 The Dow Chemical Company Pyrazolopyrimidines
US4189579A (en) * 1977-05-20 1980-02-19 The Dow Chemical Company Aminoalkylthiopurines
US4343804A (en) * 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
EP0050671B1 (en) 1980-04-28 1985-03-20 Teijin Limited Thiazolo(3,2-a)pyrimidine derivatives, process for preparing same, and drug containing same
EP0053678A1 (de) 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyanpyrazole, diese enthaltende herbizide Mittel, Verfahren zu ihrer Herstellung und ihre Anwendung als Herbizide
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
JPS6157587A (ja) * 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
CA2174080A1 (en) * 1993-10-12 1995-04-20 Paul Edward Aldrich 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
JP3036079B2 (ja) 1994-09-09 2000-04-24 日本新薬株式会社 複素環誘導体及び医薬
CA2194756A1 (en) 1995-05-12 1996-11-14 Jun Yuan Novel deazapurine derivatives; a new class of crf1 specific ligands
KR0169813B1 (ko) * 1995-07-12 1999-01-15 김종인 4-아미노-3-아실나프티리딘 유도체
JP4022271B2 (ja) 1995-10-31 2007-12-12 富士フイルム株式会社 ピラゾリルアゾフエノール色素
AU708055B2 (en) 1996-02-02 1999-07-29 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
ES2168237T3 (es) * 1996-02-07 2007-04-01 Neurocrine Biosciences, Inc. Pirazolopirimidinas como antagonistas de receptores de crf.
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
WO1998008820A1 (fr) 1996-08-26 1998-03-05 Yamanouchi Pharmaceutical Co., Ltd. Composes de benzenesulfone et sels de ces derniers
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
ATE340176T1 (de) * 1996-08-28 2006-10-15 Pfizer Substituierte 6,5-heterobicyclische-derivate
WO1998035967A2 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
ES2207834T3 (es) * 1997-04-22 2004-06-01 Janssen Pharmaceutica N.V. Quino- y quinazolinas antagonistas del crf.
NZ335823A (en) 1997-04-22 2001-06-29 Neurocrine Biosciences Inc Thiophenopyridines, preparation as CRF receptor antagonists
NL1010018C2 (nl) * 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
JP2002510687A (ja) 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ
JP2000038350A (ja) * 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
EP1105394A1 (en) * 1998-08-21 2001-06-13 Du Pont Pharmaceuticals Company ISOXAZOLO 4,5-d]PYRIMIDINES AS CRF ANTAGONISTS
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DK1212327T3 (da) * 1999-09-17 2003-12-15 Abbott Gmbh & Co Kg Pyrazolopyrimidiner som terapeutiske midler
CA2379640C (en) * 1999-09-30 2006-11-28 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
IL148905A0 (en) 1999-09-30 2002-09-12 Neurogen Corp Pfizer Inc Certain alkylene diamine-substituted pyrazolo{1,5,-a}-1,5-pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines
KR20020047201A (ko) * 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 아미노-치환된 피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
GR990100388A (el) 1999-11-09 2001-07-31 Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος....
CN1298015A (zh) 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人多肽内切酶6和编码这种多肽的多核苷酸
AU2335801A (en) 1999-12-22 2001-07-03 Merck Frosst Canada & Co. Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors
IL150632A0 (en) 2000-01-18 2003-02-12 Pfizer Prod Inc Corticotropin releasing factor antagonists
EP1268568A4 (en) 2000-02-15 2003-05-28 Foster Miller Inc RESIN COMPOSITIONS CURABLE BY RADIATION WITHOUT VOLATILE ORGANIC CONSTITUENT
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
EP1259494A4 (en) 2000-02-18 2004-09-15 Merck & Co Inc ARYLOXY ACETIC ACIDS FOR DIABETES AND LIPID DISEASES
RU2298418C2 (ru) 2000-04-12 2007-05-10 Новартис Аг Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)
DE10024319A1 (de) 2000-05-17 2001-11-22 Merck Patent Gmbh Bisacylguanidine
JP2003533530A (ja) 2000-05-18 2003-11-11 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニスト
EP1287133B1 (en) 2000-05-18 2006-12-13 Bayer HealthCare AG Regulation of human dopamine-like g protein-coupled receptor
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2002002539A1 (en) 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
DE60128475T2 (de) 2000-07-25 2008-02-07 Merck & Co., Inc. N-substituierte indole mit anwendung in der behandlung von diabetes
AU2001284417A1 (en) * 2000-09-05 2002-03-22 Taisho Pharmaceutical Co. Ltd. Hair growth stimulants
DE60129573T2 (de) 2000-09-20 2008-04-17 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US20030224058A1 (en) 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
EP1347755A2 (en) 2000-10-31 2003-10-01 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
JP2004529075A (ja) 2000-11-03 2004-09-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれに関する方法
US20020058026A1 (en) 2000-11-13 2002-05-16 Milton Hammerly HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
EP1340749A4 (en) 2000-11-17 2007-09-05 Takeda Pharmaceutical isoxazole
ATE470662T1 (de) 2000-11-20 2010-06-15 Biovitrum Ab Publ Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
EP1347971B1 (en) 2000-12-21 2006-03-01 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
RU2756946C2 (ru) 2001-01-26 2021-10-07 Мерк Шарп И Доум Корп. Применение замещенных азетидинонов для лечения ситостеролемии
WO2002060388A2 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
US7342021B2 (en) * 2001-02-08 2008-03-11 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
AU2002251978B2 (en) 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
WO2002072101A1 (en) 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
ES2332505T3 (es) 2001-06-01 2010-02-08 F. Hoffmann-La Roche Ag Derivados de pirimidina, triazina y pirazina como receptores de glutamato.
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
EP1406872B1 (en) 2001-06-20 2007-12-19 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
AU2002310465B2 (en) 2001-06-20 2006-06-15 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
GB2393825B (en) 2001-08-02 2006-02-15 Halliburton Energy Serv Inc Adaptive acoustic transmitter controller apparatus and method
WO2003026661A1 (fr) 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
EP1438048A1 (en) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US20070225351A1 (en) 2002-01-11 2007-09-27 Lippa Arnold S Methods and compositions for controlling body weight and appetite
GB0201850D0 (en) 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
DE60336901D1 (de) 2002-03-07 2011-06-09 X Ceptor Therapeutics Inc Chinazolinon modulatoren von nukleinrezeptoren
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2003103632A1 (en) 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
JP5219329B2 (ja) 2002-06-28 2013-06-26 ネステク、リミテッド 下痢の予防又は治療用の医薬組成物
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
ATE451369T1 (de) 2002-07-15 2009-12-15 Merck & Co Inc Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
WO2004009597A2 (en) 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as protein kinase inhibitors
AU2003261204A1 (en) 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
WO2004009596A2 (en) 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
AU2003258542A1 (en) 2002-07-29 2004-02-23 Axxima Pharmaceuticals Ag Method for isolating atp binding proteins by means of immobolized protein inhibitors
DE60322075D1 (de) 2002-07-30 2008-08-21 Merck & Co Inc Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
EP1539137B1 (en) 2002-07-30 2010-05-26 Merck Sharp & Dohme Corp. Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
PL376372A1 (en) 2002-08-08 2005-12-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2003256419A1 (en) 2002-08-21 2004-03-11 Merck & Co., Inc. Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
JP4377815B2 (ja) 2002-08-29 2009-12-02 メルク エンド カムパニー インコーポレーテッド 抗糖尿病活性を有するインドール類
CA2495915A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
AU2003284111A1 (en) 2002-10-09 2004-05-04 Genaissance Pharmaceuticals, Inc. Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
JP2006504755A (ja) 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US20040110241A1 (en) 2002-12-06 2004-06-10 Segal Mark S. Materials and methods for monitoring vascular endothelial function
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AU2003299790A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
JP2006515334A (ja) 2003-01-16 2006-05-25 エスビー ファームコ プエルト リコ インコーポレーテッド ＣＲＦ受容体アンタゴニストとしてのヘテロアリール置換ピロロ［２，３−ｂ］ピリジン誘導体
US7319170B2 (en) 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
JP2004269469A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
JP2004269468A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
EA200501376A1 (ru) 2003-03-28 2006-04-28 Пфайзер Продактс Инк. Производные 1,2,4-замещённых 1,2,3,4-тетрагидро- и 1,2-дигидрохинолинов и 1,2,3,4-тетрагидрохиноксалина в качестве ингибиторов сетр для лечения атеросклероза и тучности
TWI393560B (zh) 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
DE60333546D1 (de) * 2003-05-06 2010-09-09 Univ Palackeho PyrazoloÄ4,3-DÜpyrimidines, verfahren zur ihre herstellung und deren verwendung
US7083933B1 (en) * 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
WO2004110375A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of diabetes
EP1635773A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. (a New Jersey corp.) Combination therapy for the treatment of hypertension
CA2532971A1 (en) * 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
PT1699800E (pt) 2003-12-23 2010-04-12 Novartis Ag Inibidores de quinase p-38 heterocíclicos bicíclicos
NZ547965A (en) 2003-12-24 2009-12-24 Prosidion Ltd 1,2,4-Oxadiazole derivatives as GPCR receptor agonists
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
CA2568451A1 (en) 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2006034446A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
EP1796669B1 (en) 2004-10-01 2010-09-22 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
WO2006052566A2 (en) 2004-11-03 2006-05-18 Arena Pharmaceuticals, Inc. Gpr41 and modulators thereof for the treatment of insulin-related disorders
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
CN101107245A (zh) 2005-01-19 2008-01-16 神经能质公司 经杂芳基取代的哌嗪-吡啶类似物
ATE527253T1 (de) 2005-07-01 2011-10-15 Irm Llc Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
TW200745055A (en) 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
PT1984344E (pt) 2005-12-29 2012-12-21 Lexicon Pharmaceuticals Inc Derivados de aminoácidos multicíclicos e métodos para a sua utilização
BRPI0621226A2 (pt) 2006-01-19 2012-07-10 Orchid Reseach Lab Ltd compostos heterociclos
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas

Also Published As

Publication number Publication date
MXPA06000554A (es) 2006-07-03
NO20060688L (no) 2006-04-07
JP4920410B2 (ja) 2012-04-18
US7132426B2 (en) 2006-11-07
AU2004257267B2 (en) 2009-12-03
EP2292620A2 (en) 2011-03-09
CR8118A (es) 2006-05-31
US20050059650A1 (en) 2005-03-17
US20070072844A1 (en) 2007-03-29
EP2292620A3 (en) 2011-06-22
US20060142262A1 (en) 2006-06-29
IL172621A0 (en) 2006-04-10
AR053863A2 (es) 2007-05-23
EP1644375A2 (en) 2006-04-12
BRPI0412689A (pt) 2006-10-03
IS8295A (is) 2006-02-13
EP2287165A2 (en) 2011-02-23
JP2007531698A (ja) 2007-11-08
US20070082874A1 (en) 2007-04-12
TNSN06005A1 (en) 2007-10-03
EP2287166A3 (en) 2011-06-22
ECSP066284A (es) 2006-07-28
US8410119B2 (en) 2013-04-02
CN102417508A (zh) 2012-04-18
RS20060018A (en) 2007-12-31
JP2011068697A (ja) 2011-04-07
NZ544200A (en) 2009-07-31
US7625906B2 (en) 2009-12-01
KR20060056944A (ko) 2006-05-25
TW200524934A (en) 2005-08-01
MY157911A (en) 2016-08-15
CA2532971A1 (en) 2005-01-27
MA28130A1 (fr) 2006-09-01
US20100093761A1 (en) 2010-04-15
EA200600240A1 (ru) 2006-08-25
WO2005007658A3 (en) 2005-06-16
EP2287166A2 (en) 2011-02-23
EP2287165A3 (en) 2011-06-22
EA010023B1 (ru) 2008-06-30
WO2005007658A2 (en) 2005-01-27
AU2004257267A1 (en) 2005-01-27
TWI335328B (en) 2011-01-01

Similar Documents

Publication Publication Date Title
AR045697A1 (es) Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
HRP20090093T3 (en) Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
AR045047A1 (es) Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
HRP20080592T3 (en) 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
HRP20060100T3 (en) Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
AR077143A1 (es) Compuestos insecticidas
AR048939A1 (es) Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios.
AR039257A1 (es) Derivados de benzamida
AR069489A1 (es) Derivados de 3-(bencilsulfinil)-5,5-dimetil-4,5-dihidroisoxazol y derivados de 5,5-dimetil-3-[(1h-pirazol-4-ilmetil)sulfinil]-4,5-dihidroisoxazol quirales, proce-dimientos para su preparacion asi como su uso como herbicidas y como re-guladores del crecimiento de las plantas
AR080233A1 (es) Derivados de dihidrofurano como compuestos insecticidas
AR055554A1 (es) Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos
HRP20140975T1 (hr) Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
CO6170361A2 (es) Composiciones y metodos para modular receptores de c-kit y pdgfr
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
AR056917A1 (es) Procedimientos para preparar eteres aromaticos
AR054360A1 (es) Derivados de tiazol como herbicidas
AR070636A1 (es) Derivados de piridina, composicion farmaceutica y uso terapeutico
AR060658A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
EA200970670A1 (ru) Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс
AR069678A1 (es) Compuestos de piranodiona, tiopiranodiona y ciclohexanotriona como herbicidas
BRPI0907122B8 (pt) compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
EA201100368A1 (ru) Амидные соединения, полезные в терапии
HRP20231608T1 (hr) Derivati piridinil sulfonamida, njihovi farmaceutski pripravci i njihove uporabe
AR068976A1 (es) Derivados de 2-[2-(fenil)etilamino]alcanoamida substituidos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal